Generic Name and Formulations:
Theophylline 100mg, 200mg, 300mg, 400mg; ext-rel caps.
- Two Independent Variables Found to Be Prognostic in Diffuse Large B-Cell Lymphoma
- Adjuvant Sunitinib in Renal Cell Carcinoma May Increase Symptoms, Reduce Health Quality Scores
- Harnessing the Power of Both Alemtuzumab and Rituximab in a Bispecific Antibody
- Esophageal and Esophagogastric Junction Cancer Treatment Regimens
- Multiple Myeloma Treatment Regimens
- Insulin Products
Indications for THEO-24:
Asthma. Chronic bronchitis. Emphysema.
See literature. Swallow whole. Stabilized patients may be switched from immediate-release or controlled-release product to once- or twice-daily dosing with Theo-24 on a mg/mg basis. Do not take within 1 hour of fatty food if on high dose. Max without serum level monitoring: 12–15years: 16mg/kg (max 400mg) per day; ≥16years: 400mg/day.
Not for primary treatment of acute attack. Active peptic ulcer. Arrhythmias. Seizure disorders. Hepatic dysfunction. CHF. Acute pulmonary edema. Cor pulmonale. Hypothyroidism. Fever. Sepsis. Shock. Monitor serum levels; do not try to maintain non-tolerated doses. Rapid metabolizers. Infants (<3 months of age) with reduced renal function. Neonates. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
See literature. Smokers have increased metabolism. Potentiated by quinolones, macrolides, enoxacin, cimetidine, alcohol, allopurinol, estrogen oral contraceptives, tacrine, interferon alpha, disulfiram, fluvoxamine, verapamil, mexiletine, methotrexate, pentoxifylline, propafenone, ticlopidine, thiabenazole. Antagonized by phenytoin, rifampin, barbiturates, carbamazepine, aminogluthethimide, moricizine, St. John's wort, isoproterenol, sulfinpyrazone. Avoid β-blockers. Antagonizes lithium, benzodiazepines, pancuronium, adenosine. Toxicity with sympathomimetics. Seizures with ketamine. Arrhythmias with halothane.
GI upset, headache, CNS stimulation, diuresis, arrhythmias, seizures.
Caps 100mg, 400mg—100; 200mg, 300mg—100, 500
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline